AstraZeneca's COPD drug tozorakimab has delivered positive results in two late-stage trials, with full data reinforcing hopes it could become a breakthrough treatment, CNBC reported.
Key facts
- AstraZeneca's COPD drug tozorakimab scored wins in two late-stage trials, according to CNBC.
- CNBC reported the full data reinforces hopes the drug could be a breakthrough COPD treatment.
- AstraZeneca has a peak annual sales forecast of more than $5 billion for the drug, per CNBC.
- The results were reported by CNBC on 8 September 2026.
AstraZeneca’s chronic obstructive pulmonary disease (COPD) treatment, tozorakimab, has achieved positive results in two late-stage clinical trials, according to CNBC.
CNBC reported that the full data reinforces hopes the drug could be a breakthrough COPD treatment.
According to CNBC, the full data supports AstraZeneca’s peak annual sales forecast of more than $5 billion for the drug.
Why it matters
CNBC reported that the full data reinforces hopes tozorakimab could be a breakthrough COPD treatment and reach AstraZeneca's peak annual sales forecast of more than $5 billion.
Frequently asked questions
What is the name of AstraZeneca's COPD drug?
The drug is tozorakimab, which AstraZeneca is developing as a treatment for chronic obstructive pulmonary disease (COPD).
How much could the drug earn for AstraZeneca?
According to CNBC, AstraZeneca has a peak annual sales forecast of more than $5 billion for the drug.
What were the trial results?
CNBC reported that the drug scored wins in two late-stage trials, with full data reinforcing hopes it could be a breakthrough COPD treatment.